The potentially variable tissue-specific effects of EFEMP1 on cancer patient prognosis are reflected in the corresponding tissue-derived cancer in vitro assays, revealing the ability of EFEMP1 to either activate [13] or suppress [9] AKT signaling activity in pancreatic or nasopharyngeal carcinoma cell lines, respectively. The gene discussed is AKT1; the disease is nasopharyngeal carcinoma.